The Week in Biopharma, Feb 14-21
Contract Development and Manufacturing Organizations (CDMO)
- Center for Breakthrough Medicines Launches Analytical Testing Services (USA)
- Piramal Pharma Strengthens North American Capabilities (USA)
- Catalent Expands Shanghai Facility (China)
- Resilience Enters Collaboration with Takeda (USA)
- Hoth Therapeutics Selects Nuvisan to Manufacture Clinical Batches of HT-001 (France)
- Angus Expands Louisiana Site to Include Commercial Production of Tris Amino HCI Products (USA)
- Thermo Fisher Introduces New Cell and Gene Therapy Services (USA)
- Leiters Acquires Facility to Increase Manufacturing Capacity (USA)
- Integrity Bio and LakePharma Become Curia (USA)
- Recipharm grows biologics business as it acquires Arranta Bio and Vibalogics (USA)
Artificial Intelligence (AI)
- Genuv Teams With Aiforia To Create An AI-Powered Version Of Its ATRIVIEW® Drug Screening Platform (South Korea)
Biopharm
- Moderna and ROVI Expand mRNA Manufacturing Collaboration (Spain)
- Northwest Biotherapeutics Begins Cancer Vaccine Production (UK)
- Accord Healthcare Launches Additional Strengths of Hydroxychloroquine Tablets (USA)
- Robert Califf Confirmed to Lead FDA (USA)
- ImmunityBio Acquires Manufacturing Facility in New York (USA)
- Collegium Purchases BioDelivery Sciences International in All-Cash Deal (USA)
- IASO, Innovent CART-cell Therapy Gets Orphan Designation (USA)
- Lilly’s Bebtelovimab Receives EUA to Treat COVID-19 (USA)
- Kalbe and Amarox partner to market Covid-19 drug (Indonesia)
- BMS’ Breyanzi sBLA receives FDA priority review for large B-cell lymphoma (USA)
- Electra raises $84m to advance the clinical development of ELA026 (Israel)
- AstraZeneca’s Saphnelo gets approval in the EU for SLE (UK)
- Moderna’s Covid-19 vaccine gets authorisation in Australia for children (Australia)
- Ligand to spin off J&J-partnered antibody unit with $70M funding (USA)
- After clinical hold, Yumanity to cut 60% of workforce by April and hunt for a buyer (USA)
- Remix Therapeutics signs Janssen licensing deal that could top $1B (USA)
- Single-asset Equillium buys Bioniz for up to $329M, adding 3 drugs to its pipeline (USA)
- Third Harmonic Bio raises $105M in series B to push hives treatment through phase 1b (USA)
- Merck gets ahead of the Curve, inking oncology and neurology drug discovery deal with emerging British biotech (UK)
- ShouTi Introduces Basecamp Bio as a Wholly Owned Subsidiary to Expand Pipeline and Partnerships (USA)
- Awakn Life Sciences Drug Discovery Program Files Patent Application for a New Class of Entactogen-Like Molecules (Canada)
- Saguaro Closes $1.1M Start-Up Funding to Offer New Drug Discovery Technologies That Help Fight Human Disease (USA)
- Pasadena Biotech Terray Raises $60 Million to Speed Up Drug Discovery (USA)
- Discovery Life Sciences Streamlines Cell and Gene Therapy Manufacturing with Expanded Human Cellular Starting Materials (USA)
- BBC, Cytiva collaborate to setup training platform in bioprocessing (India)
